sipatrigine

Known as: 4-amino-2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)pyrimidine 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2017
012319932017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Major depressive disorder (MDD) is a chronic, recurring and potentially life-threatening mental illness. Current treatments are… (More)
Is this relevant?
2004
2004
Sodium channel blockers are neuroprotective against cerebral ischemia in animal models. A novel neuroprotective compound AM-36… (More)
Is this relevant?
2003
2003
Relatively little has been published on the pharmacology of R-type and T-type Ca(2+) channels. Here, whole-cell Ca(2+) channel… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Alanine-scanning mutagenesis of transmembrane segments IS6 and IIS6 of the rat brain Na(v)1.2 channel alpha subunit identified… (More)
Is this relevant?
2002
2002
Excessive nitric oxide formation may contribute to the pathology occurring in diseases affecting central white matter, such as… (More)
Is this relevant?
2001
2001
We have cloned and functionally expressed the human orthologue of the mouse TRAAK gene. When cDNA for hTRAAK is expressed in… (More)
Is this relevant?
2001
2001
Acidic extracellular pH reduced high-voltage-activated (HVA) currents in freshly isolated cortical pyramidal neurones of adult… (More)
Is this relevant?
2000
2000
BACKGROUND The sodium channel blocker sipatrigine (619C89) prevents ischemia-induced glutamate release and is neuroprotective in… (More)
Is this relevant?
2000
2000
Sipatrigine (BW619C89), a derivative of the antiepileptic agent lamotrigine, has potent neuroprotective properties in animal… (More)
Is this relevant?
1993
1993
BACKGROUND AND PURPOSE The excitatory amino acid neurotransmitter glutamate is involved in excitotoxic brain injury and… (More)
Is this relevant?